tag:blogger.com,1999:blog-8550428.post114380604731571027..comments2024-03-27T01:34:23.434-04:00Comments on Pharma Marketing Blog: DTC without the RiskVladhttp://www.blogger.com/profile/04114063498108633047noreply@blogger.comBlogger1125tag:blogger.com,1999:blog-8550428.post-1144160233317197682006-04-04T10:17:00.000-04:002006-04-04T10:17:00.000-04:00The CHC's argument is absurd on its face. The log...The CHC's argument is absurd on its face. The logic behind it could equally be used to argue that we should also eliminate the FDA-approved label, except for physicians. The army of pharamaceutical salespeople gives the lie to the notion of a dispassionate and independent learned intermediary. With the debacles of the past two years -- Vioxx, Celebrex, Paxil, and on and on, how can anyone be arguing for <B>less</B> disclosure to patients? If this is the position of the industry, then they are virtually inviting Congress to legislate limits on DTCA. Given Congress' recent inquiries into much at the FDA -- the refusal to approve OTC Plan B, the questions re: the VNS device approval -- you'd think the industry would be trying to mollify them (e.g. PhRMA DTC "guidelines") rather than inflame them. <BR/><BR/>It's like watching a train wreck...Anonymousnoreply@blogger.com